Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Applications of antisense oligonucleotides for the treatment of inherited retinal diseases.

Current opinion in ophthalmology - 1 May 2017

Collin Rob W J, Garanto Alejandro

Abstract excerpt

PURPOSE OF REVIEW: Over the last years, antisense oligonucleotides (AONs) have gained attention as a therapeutic tool for the treatment of ocular diseases such as cytomegalovirus retinitis, keratitis-induced corneal neovascularization, and inherited retinal diseases (IRDs). In this review, we summarize the recent key findings, and describe the challenges and opportunities that lie ahead to translate AON-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Exons
Share to RHO gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Mutation

Share to Oligonucleotides, Antisense

Share to Retinal Development and Disorders

Share to Retinal Diseases

Source

Identifiers

PMID: 28151748
DOI: 10.1097/ICU.0000000000000363

Genes

RHO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Applications of antisense oligonucleotides for the treatment of inherited retinal diseases.PMID 28151748Read ↗

Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases.Semantic proximity Read ↗

RNA therapeutics for retinal diseasesSemantic proximity Read ↗

Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.Semantic proximity Read ↗

In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery.Semantic proximity Read ↗

Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.Semantic proximity Read ↗

Advances in Precision Therapeutics and Gene Therapy Applications for Retinal Diseases: Impact and Future DirectionsSemantic proximity Read ↗

Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa.Semantic proximity Read ↗

Gene therapy for inherited retinal diseasesSemantic proximity Read ↗

Splice-Modulating Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A>G LCA10 ModelsSemantic proximity Read ↗

Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes.Semantic proximity Read ↗

Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnologySemantic proximity Read ↗

Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.